Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 8.1% – Here’s Why

Tiziana Life Sciences Ltd (NASDAQ:TLSA)’s stock price shot up 8.1% on Monday . The company traded as high as $1.38 and last traded at $1.33. 384,307 shares were traded during trading, an increase of 137% from the average session volume of 162,267 shares. The stock had previously closed at $1.23.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TLSA. Weiss Ratings lowered shares of Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Wall Street Zen cut shares of Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Tiziana Life Sciences Price Performance

The firm’s 50 day moving average price is $1.31 and its two-hundred day moving average price is $1.36.

Tiziana Life Sciences (NASDAQ:TLSA) last posted its quarterly earnings results on Friday, May 1st. The company reported ($0.28) earnings per share for the quarter.

Institutional Investors Weigh In On Tiziana Life Sciences

A number of hedge funds have recently added to or reduced their stakes in TLSA. Marshall Wace LLP lifted its holdings in shares of Tiziana Life Sciences by 5.2% in the 4th quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock worth $420,000 after purchasing an additional 14,005 shares in the last quarter. Millennium Management LLC acquired a new position in Tiziana Life Sciences during the third quarter worth $520,000. Jane Street Group LLC grew its holdings in shares of Tiziana Life Sciences by 968.2% during the first quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock valued at $181,000 after buying an additional 151,858 shares during the last quarter. Zhang Financial LLC increased its position in shares of Tiziana Life Sciences by 12.0% during the first quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock worth $131,000 after acquiring an additional 12,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Tiziana Life Sciences by 413.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock worth $164,000 after acquiring an additional 88,830 shares in the last quarter.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.